Therapy Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name CLN-619 + Datopotamab deruxtecan
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
CLN-619 CLN 619|CLN619 CLN-619 is a humanized monoclonal antibody that targets MICA/MICB, potentially resulting in antitumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr 3506).
Datopotamab deruxtecan Datroway Dato-DXd|DS1062a|DS 1062a|DS-1062a|datopotamab deruxtecan-dlnk TROP2 Antibody 18 Datroway (datopotamab deruxtecan) is an antibody-drug conjugate (ADC) comprising an antibody that targets TROP2 linked to the topoisomerase I inhibitor DXd, which may induce apoptosis and inhibit tumor growth (PMID: 34413126). Datroway (datopotamab deruxtecan) is FDA-approved for use in patients with unresectable or metastatic, hormone receptor-positive, ERBB2 (HER2)-negative breast cancer who have received prior endocrine-based therapy and chemotherapy, and in patients with locally advanced or metastatic EGFR-mutant non-small cell lung cancer who have received prior EGFR-directed therapy and platinum-based chemotherapy (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05117476 Phase I CLN-619 Carboplatin + CLN-619 + Paclitaxel + Pemetrexed Disodium CLN-619 + Pembrolizumab CLN-619 + Datopotamab deruxtecan A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MICA) Active, not recruiting USA | POL | ESP | AUS 0


Additional content available in Icon for CKB-BoostCKB BOOST